Heart failure & cardiomyopathies
Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan
Authors' conclusion
MR-proAD concentrations rise substantially following treatment with Sac/Val, in contrast to no change from valsartan. Change in MR-proADM from neprilysin inhibition did not correlate with improvements in cardiac structure and function or health status.
Study context
- Population
- Patients with heart failure with reduced ejection fraction (HFrEF) treated with Sac/Val and patients with heart failure with preserved ejection fraction (HFpEF) randomized to Sac/Val or valsartan156 HFrEF
- Comparison
- Sac/Val vs valsartan
- HFrEF Sac/Valn = 156
- Primary endpoint
- Change in MR-proADM
- Follow-up
- 12 weeks
Primary result
As reported in the abstract
HFrEF Sac/Val
49%
median increase
HFpEF Sac/Val
60%
median increase
Valsartan
2%
median
Further findings
Median, nmol/L
| Outcome | HFrEF Sac/Val | HFpEF Sac/Val |
|---|---|---|
| Baseline MR-proADM | 0.80 (IQR 0.59–0.99) | 0.88 (IQR 0.68–1.20) |
Correlates of mid-regional pro-adrenomedullin (MR-proADM) change
- Greater increases associated with higher Sac/Val doses
- Weak correlation with changes in NT-proBNP, cardiac troponin T and urinary cGMP
- Increases associated with decreases in BP
- Not significantly associated with changes in echocardiographic parameters or health status
Original publication
Changes in Mid-Regional Pro-Adrenomedullin During Treatment with Sacubitril/Valsartan. Eur J Heart Fail. Published 11 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →